BRADSHAW: Automated Molecular Design for ERAP1 Inhibitor Optimization

Robert P. Law published a dataset on figshare in 2026 detailing a pilot project for automated molecular design. The 5.8 KB CSV file documents the application of the BRADSHAW platform to optimize inhibitors of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), a target in cancer immunotherapy and autoimmune diseases. The work involved four iterations of generative design, machine learning model refinement, and multiparameter optimization.

Use Cases

• Benchmarking generative molecular design platforms based on the documented BRADSHAW application.
• Studying multiparameter optimization strategies for drug candidates based on the described focus on potency, physicochemical properties, and pharmacokinetics.
• Analyzing the iterative refinement of machine learning models for molecular property prediction as described in the pilot project.
• Investigating human factors in computational medicinal chemistry projects based on the author's reflections mentioned in the description.

Strengths

• Dataset is small (5.8 KB), facilitating quick download and inspection.
• Focus is clearly defined on optimizing ERAP1 inhibitors for cancer immunotherapy and autoimmune diseases.
• Describes a complete pilot project involving four consecutive design iterations and model refinements.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Robert P. Law via figshare.

Collection Method

Generated through in silico molecular generation, property prediction, and filtering on the BRADSHAW platform.

Time Range

Temporal coverage of the underlying project is not specified.

Freshness

Last updated 2026-04-13 16:35:00; freshness should be verified.

Geography

Spatial coverage is not specified.